在2型糖尿病患者中使用SNP集群对甲福明单一治疗的血糖反应
Wayne Huey-Herng Sheu1,2,3,4,5, Chun-Yi Lee1, Yi-Wen Wang1
1Institute of Molecular and Genomic Medicine, National Health Research Institutes, Zhunan, Taiwan.
Diabetes, obesity & metabolism
|August 22, 2025
概括
来自β细胞功能障碍集群的多基因风险评分 (PRS) 可以预测2型糖尿病 (T2D) 的甲福林反应. 这种遗传方法可以指导个性化T2D治疗策略,以更好地控制血糖.
科学领域:
- 遗传学
- 代谢疾病
- 药物基因组学
背景情况:
- 2型糖尿病 (T2D) 的治疗通常涉及甲胺,但个体反应有所不同.
- 确定对甲胺血糖反应的预测因子对于优化T2D治疗至关重要.
- 多基因风险评分 (PRS) 是基于遗传倾向的患者分层的一个潜在工具.
研究的目的:
- 在新诊断的T2D患者中,研究特定单核酸多态 (SNP) 集群产生的PRS与对甲胺的血糖反应之间的关联.
- 评估PRS是否可以预测在甲福明单一治疗后的空腹血糖 (FBG) 和糖化血红蛋白 (HbA1c) 水平的变化.
主要方法:
- 对台湾精准医学倡议数据集的回顾性分析.
- 在6个月的甲福明单一治疗后评估血糖参数 (FBG,HbA1c).
- 与贝塔细胞功能障碍相关的SNP群体中最低 (Q1) 和最高 (Q5) PRS数量之间的血糖反应的比较.
主要成果:
- 从贝塔细胞功能障碍集群 (具有积极和消极的亲胰岛素关联) 获得的PRS在Q1和Q5之间观察到FBG水平的显著差异.
- 在考虑结合的β细胞功能障碍集群时,在PRS (Q1) 较低的个体中发现了较低的FBG水平.
- 在贝塔细胞功能障碍集群中,Q1组与Q5组相比记录了HbA1c值的降低,显示出负面的亲胰岛素相关性.
结论:
- 来自β细胞功能障碍SNP集群的PRS显示在T2D中预测血糖反应的潜力.
- 这些发现支持开发2型糖尿病的基因导向治疗策略.
- 进一步的研究可以探索PRS在个性化治疗中的临床实用性.
相关概念视频
Oral Hypoglycemic Agents: Biguanides and Glitazones
291
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
291
Diabetes Mellitus: Type 2 and Gestational
2.9K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.9K
Carbohydrate Metabolism
11.7K
Carbohydrates are polymers composed of molecules containing atoms of carbon, hydrogen and oxygen. One gram of carbohydrate can provide four kilo-calories of energy, which makes it the most efficient instant energy source.
Starch accounts for approximately 60% of the carbohydrates consumed by humans. Since amylase enzymes cannot function in the stomach's acidic environment, starch can only be digested in the mouth and small intestine. Simple sugars are found naturally in milk and fruits in...
Starch accounts for approximately 60% of the carbohydrates consumed by humans. Since amylase enzymes cannot function in the stomach's acidic environment, starch can only be digested in the mouth and small intestine. Simple sugars are found naturally in milk and fruits in...
11.7K
Genome-wide Association Studies-GWAS
14.1K
Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
GWAS does not require the identification of the target gene involved in...
14.1K
Dipeptidyl Peptidase 4 Inhibitors
256
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
256
Diabetes: Management and Pharmacotherapy
362
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
362


